Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02395536 · ClinicalTrials.gov registry record · NA
Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States
A NA study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Completed
- Registry status
- NA
- Development phase
- 525
- Enrollment target
NCT02395536 is a NA study that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 525 participants.
The verdict
NCT02395536, a NA study, has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- COMPLETED
- Registry status
- NA
- Development phase
- 525 participants
- Enrollment target
Study Summary
The primary purpose of the RIO 2 study is to demonstrate that when the Reveal LINQ™ insertable cardiac monitoring (ICM) system that records subcutaneous ECG insertion procedure performed in the in-office setting is as safe as LINQ™ insertions performed in the traditional hospital setting (operating room, cardiac catheterization or electrophysiology (EP) laboratory).
Interventions
- OTHER office setting
- OTHER hosptial setting
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 525 participants |
| Start Date | 2015-03-30 |
| Est. Completion | 2016-05-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02395536
The ClinicalTrials.gov registry entry for NCT02395536 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 525 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Rhythm and Heart Failure, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which office setting is the first listed.
NCT02395536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02395536 about?
NCT02395536 is a clinical study titled "Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States". The primary purpose of the RIO 2 study is to demonstrate that when the Reveal LINQ™ insertable cardiac monitoring (ICM) system that records subcutaneous ECG insertion procedure performed in the in-office setting is as safe as LINQ™ insertions performed in the traditional hospital setting (operating ...
What is the current status of trial NCT02395536?
This trial is currently completed. It is a NA study. The enrollment target is 525 participants. The study started on 2015-03-30. Estimated completion is 2016-05-31.
What interventions are being tested in trial NCT02395536?
The interventions under investigation include: office setting (OTHER), hosptial setting (OTHER).
Who is sponsoring clinical trial NCT02395536?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.